JP2017531687A5 - - Google Patents

Download PDF

Info

Publication number
JP2017531687A5
JP2017531687A5 JP2017522502A JP2017522502A JP2017531687A5 JP 2017531687 A5 JP2017531687 A5 JP 2017531687A5 JP 2017522502 A JP2017522502 A JP 2017522502A JP 2017522502 A JP2017522502 A JP 2017522502A JP 2017531687 A5 JP2017531687 A5 JP 2017531687A5
Authority
JP
Japan
Prior art keywords
cells
population
modified human
modified
immune system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017522502A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531687A (ja
JP7005346B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/057652 external-priority patent/WO2016069647A1/en
Publication of JP2017531687A publication Critical patent/JP2017531687A/ja
Publication of JP2017531687A5 publication Critical patent/JP2017531687A5/ja
Application granted granted Critical
Publication of JP7005346B2 publication Critical patent/JP7005346B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017522502A 2014-10-27 2015-10-27 養子細胞免疫療法の有効性を増強させるための組成物および方法 Active JP7005346B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462069168P 2014-10-27 2014-10-27
US62/069,168 2014-10-27
PCT/US2015/057652 WO2016069647A1 (en) 2014-10-27 2015-10-27 Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy

Publications (3)

Publication Number Publication Date
JP2017531687A JP2017531687A (ja) 2017-10-26
JP2017531687A5 true JP2017531687A5 (https=) 2018-12-06
JP7005346B2 JP7005346B2 (ja) 2022-02-04

Family

ID=54545485

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017522502A Active JP7005346B2 (ja) 2014-10-27 2015-10-27 養子細胞免疫療法の有効性を増強させるための組成物および方法

Country Status (14)

Country Link
US (1) US10828352B2 (https=)
EP (1) EP3212223B1 (https=)
JP (1) JP7005346B2 (https=)
KR (1) KR102357004B1 (https=)
CN (1) CN107106611B (https=)
AU (1) AU2015339402B2 (https=)
BR (2) BR112017008710A8 (https=)
CA (1) CA2965347C (https=)
ES (1) ES2897731T3 (https=)
HK (1) HK1243631A1 (https=)
MX (1) MX389823B (https=)
NZ (1) NZ731279A (https=)
RU (1) RU2716716C2 (https=)
WO (1) WO2016069647A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012305931B2 (en) 2011-09-08 2017-09-07 Yeda Research And Development Co. Ltd Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
JP6375289B2 (ja) 2012-04-05 2018-08-15 マサチューセッツ インスティテュート オブ テクノロジー 免疫刺激組成物およびその使用方法
CA2945320A1 (en) 2014-04-10 2015-10-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Drug regulated transgene expression
JP6865688B2 (ja) 2015-01-16 2021-04-28 ジュノー セラピューティクス インコーポレイテッド Ror1に特異的な抗体およびキメラ抗原受容体
JP7057748B2 (ja) 2015-07-16 2022-04-20 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド 遺伝子改変された抗第三者中枢性メモリーt細胞および免疫療法におけるその使用
RU2018106515A (ru) 2015-07-21 2019-08-21 Зе Чилдрен'С Медикал Сентер Корпорейшн Pd-l1-экспрессирующие гемопоэтические стволовые клетки и применения
WO2017027291A1 (en) 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
EA201891066A1 (ru) 2015-10-30 2018-10-31 ЭнБиИ-ТЕРАПЬЮТИКС АГ Антитела к ror1
SG11201806120WA (en) 2016-01-20 2018-08-30 Scripps Research Inst Ror1 antibody compositions and related methods
CN108699149B (zh) 2016-02-02 2023-01-06 弗雷德哈钦森癌症中心 抗-ror1抗体及其用途
CA3022267A1 (en) 2016-05-04 2017-11-09 Fred Hutchinson Cancer Research Center Cell-based neoantigen vaccines and uses thereof
MA45025A (fr) * 2016-05-20 2019-03-27 Lilly Co Eli Traitement d'association utilisant des inhibiteurs de notch et de pd-1 ou pd-l1
CN106199005B (zh) * 2016-07-26 2019-02-01 浙江大学 采用cd137表达量检测淋巴细胞抗大肠癌活性的方法
BR112019011065A2 (pt) 2016-12-03 2019-10-01 Juno Therapeutics Inc métodos para determinação da dosagem de células t car
AU2017370644A1 (en) 2016-12-05 2019-06-13 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
CN110392736A (zh) * 2017-01-18 2019-10-29 耶达研究及发展有限公司 遗传修饰的反抑细胞及其在免疫治疗中的用途
CN107267555B (zh) * 2017-05-27 2020-03-20 上海优卡迪生物医药科技有限公司 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用
EP3665193A1 (en) 2017-08-07 2020-06-17 NBE Therapeutics AG Anthracycline-based antibody drug conjugates having high in vivo tolerability
KR20200035104A (ko) * 2017-08-11 2020-04-01 프레드 헛친슨 켄서 리서치 센터 Braf 특이적 tcr 및 그의 용도
WO2019060425A1 (en) * 2017-09-19 2019-03-28 Massachusetts Institute Of Technology COMPOSITIONS FOR CHIMERIC ANTIGENIC RECEPTOR T CELL THERAPY AND USES THEREOF
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
WO2019067504A1 (en) * 2017-09-26 2019-04-04 Longwood University SPECIFIC CHIMERIC ANTIGEN RECEPTOR AT PD-1 AS IMMUNOTHERAPY
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
JP7517983B2 (ja) * 2017-11-20 2024-07-17 ユリウス-マクシミリアン-ウニヴェルシテート・ヴュルツブルク 非常に低レベルのcd19を発現する骨髄腫細胞を除去するcd19cart細胞
US20210198372A1 (en) 2017-12-01 2021-07-01 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
CN109810995B (zh) * 2017-12-06 2020-10-02 阿思科力(苏州)生物科技有限公司 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用
CN108148137B (zh) * 2017-12-29 2021-03-23 中国人民解放军第四军医大学 一种b7h4/1e10单克隆抗体及其应用
BR112021003830A2 (pt) * 2018-08-28 2021-07-20 Fred Hutchinson Cancer Research Center métodos e composições para terapia celular t adotiva incorporando sinalização notch induzida
CN111544585B (zh) * 2019-02-11 2024-12-27 北京卡替医疗技术有限公司 一种可助推免疫细胞在体内扩增的佐剂
EP3941511A2 (en) 2019-03-20 2022-01-26 Massachusetts Institute of Technology Uses of amphiphiles in immune cell therapy and compositions therefor
CN114007655A (zh) * 2019-06-14 2022-02-01 旗舰创业创新第六有限责任公司 用于细胞疗法的环状rna
WO2021129927A1 (en) * 2019-12-23 2021-07-01 Biontech Cell & Gene Therapies Gmbh Treatment with immune effector cells engineered to express an antigen receptor
CA3188143A1 (en) * 2020-06-25 2021-12-30 The Methodist Hospital Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
GB0224442D0 (en) 2002-10-21 2002-11-27 Molmed Spa A delivery system
US20050129671A1 (en) * 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
JP2008527001A (ja) 2005-01-13 2008-07-24 ザ ジョンズ ホプキンス ユニバーシティー 前立腺幹細胞抗原ワクチンおよびその使用
US20090324630A1 (en) * 2008-04-21 2009-12-31 Jensen Michael C Fusion multiviral chimeric antigen
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
CN110200997A (zh) * 2011-03-23 2019-09-06 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
EP2697367B1 (en) * 2011-04-13 2018-12-19 Immunicum AB Method for proliferation of antigen-specific t cells
JP6117515B2 (ja) 2011-11-01 2017-04-19 国立大学法人名古屋大学 髄膜腫治療用医薬組成物
PT2961831T (pt) * 2013-02-26 2020-10-12 Memorial Sloan Kettering Cancer Center Composições e métodos para imunoterapêutica
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
AU2014248119B2 (en) * 2013-04-03 2019-06-20 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted T-cells derived from pluripotent stem cells

Similar Documents

Publication Publication Date Title
JP2017531687A5 (https=)
RU2017114174A (ru) Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии
Johdi et al. Colorectal cancer immunotherapy: options and strategies
Baxevanis et al. Cancer immunotherapy
Wang et al. Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
Kiesgen et al. Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies
Kershaw et al. Gene-engineered T cells for cancer therapy
Spear et al. Strategies to genetically engineer T cells for cancer immunotherapy
Dai et al. Chimeric antigen receptors modified T-cells for cancer therapy
Essand et al. Genetically engineered T cells for the treatment of cancer
Kazemi et al. Immunotherapeutic approaches for cancer therapy: an updated review
JP7717686B2 (ja) キメラcd3融合タンパク質と抗cd3ベースの二重特異性t細胞活性化エレメントの複合発現
Holzinger et al. CAR T cells: a snapshot on the growing options to design a CAR
JP2022535429A (ja) 免疫療法のための操作されたナチュラルキラー細胞と操作されたt細胞の組み合わせ
JP2020509767A5 (https=)
JP2015527070A5 (https=)
CN111247241A (zh) T细胞受体缺陷型嵌合抗原受体t细胞和其使用方法
WO2012079000A4 (en) Use of chimeric antigen receptor-modified t cells to treat cancer
CN108410892A (zh) 降低由pd-l1诱导的免疫耐受性
WO2018210279A1 (zh) Toll样受体激动剂与免疫效应细胞的联用
JP2021512637A5 (https=)
JPWO2019157454A5 (https=)
Danhof et al. CARs and other T cell therapies for MM: the clinical experience
Pu et al. Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma
Garber et al. Adoptive T-cell therapy for Leukemia